Sunrest Lifescience (NSE:SUNREST) WACC %:10.51% (As of Jul. 05, 2026) — Near Median


NSE:SUNREST Sunrest Lifescience Ltd NSE:SUNREST
50 GF Score
Price ₹34.00
! 5 Warning Signs
View Full Analysis

What is Sunrest Lifescience WACC %?

Sunrest Lifescience NSE:SUNREST 50 WACC % is 10.51% as of Jul. 05, 2026, which is 0% below its 10-year median of 10.53. GuruFocus rates NSE:SUNREST with a GF Score™ of 50/100. The stock has 5 warning signs investors should review. Among 690 Healthcare Providers & Services companies, Sunrest Lifescience ranks worse than 70.87% on this metric.

As of today (2026-07-05), Sunrest Lifescience's weighted average cost of capital is 10.51%%. Sunrest Lifescience's ROIC % is 12.55% (calculated using TTM income statement data). Sunrest Lifescience generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Sunrest Lifescience  (NSE:SUNREST) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sunrest Lifescience's weighted average cost of capital is 10.51%%. Sunrest Lifescience's ROIC % is 12.55% (calculated using TTM income statement data). Sunrest Lifescience generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.


Related Terms

Sunrest Lifescience WACC % Historical Data

* Premium members only.

The historical data trend for Sunrest Lifescience's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunrest Lifescience WACC % Chart

Sunrest Lifescience Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
WACC %
Get a 7-Day Free Trial 0.00 0.00 11.56 10.21 10.53

Sunrest Lifescience Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
WACC % Get a 7-Day Free Trial Premium Member Only 0.00 11.56 11.50 10.21 10.53

Sunrest Lifescience WACC % Competitor Comparison

For the Pharmaceutical Retailers subindustry, Sunrest Lifescience's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunrest Lifescience WACC % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sunrest Lifescience's WACC % distribution charts can be found below:

* The bar in red indicates where Sunrest Lifescience's WACC % falls into.


NSE:SUNREST
50GF Score
Sunrest Lifescience Ltd NSE:SUNREST
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunrest Lifescience WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Sunrest Lifescience's market capitalization (E) is ₹163.497 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Sunrest Lifescience's latest one-year semi-annual average Book Value of Debt (D) is ₹147.5445 Mil.
a) weight of equity = E / (E + D) = 163.497 / (163.497 + 147.5445) = 0.5256
b) weight of debt = D / (E + D) = 147.5445 / (163.497 + 147.5445) = 0.4744

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 7.02%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Sunrest Lifescience's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 7.02% + 1 * 6% = 13.02%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Mar. 2026, Sunrest Lifescience's interest expense (positive number) was ₹13.998 Mil. Its total Book Value of Debt (D) is ₹147.5445 Mil.
Cost of Debt = 13.998 / 147.5445 = 9.4873%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 29.698 / 161.094 = 18.44%.

Sunrest Lifescience's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.5256*13.02%+0.4744*9.4873%*(1 - 18.44%)
=10.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 10.51% mean?
Sunrest Lifescience (NSE:SUNREST) has a WACC % of 10.51% as of Jul. 05, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Sunrest Lifescience and its competitors. This is near median its historical median of 10.53. Over the past decade, Sunrest Lifescience's WACC % has ranged from 10.21 to 11.56. According to the industry distribution chart, Sunrest Lifescience ranks #489 out of 690 companies in the Healthcare Providers & Services industry, placing it in the top 70.9%.
Is Sunrest Lifescience's WACC % too high?
Sunrest Lifescience's current WACC % of 10.51% is near median its 10-year median of 10.53. Over the past 10 years, this metric has ranged from a low of 10.21 to a high of 11.56. The Healthcare Providers & Services industry median WACC % is 8.49. Sunrest Lifescience's value of 10.51% is 23.8% above this industry median. Based on the distribution chart, Sunrest Lifescience ranks #489 out of 690 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sunrest Lifescience has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's WACC % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sunrest Lifescience ranks #489 out of 690 companies for WACC %. This places Sunrest Lifescience in the lower half of its industry. The industry median WACC % is 8.49. Sunrest Lifescience's value of 10.51% is 23.8% above this benchmark. Historically, Sunrest Lifescience's own WACC % has ranged from 10.21 to 11.56 over the past decade. While the company's 10-year median is 10.53 vs. the industry median of 8.49, Sunrest Lifescience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Healthcare Providers & Services company?
The median WACC % among Healthcare Providers & Services companies is 8.49, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunrest Lifescience's current WACC % of 10.51% is 23.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Sunrest Lifescience and its competitors. For the Healthcare Providers & Services industry, the median WACC % is 8.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunrest Lifescience's current WACC % is 10.51%, which is near median its own 10-year median of 10.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current WACC % of 10.51%. The current WACC % is 10.51%, which is near median its 10-year median of 10.53 and 23.8% above the Healthcare Providers & Services industry median of 8.49. Sunrest Lifescience's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current WACC % is 10.51% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunrest Lifescience Business Description

Address YMCA Club, Near SG Highway, D-608 West Gate, Near Brooklin Tower, Makarba, Jivraj Park, Ahmedabad, GJ, IND, 380051
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
50GF Score

Get the complete analysis for NSE:SUNREST

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹34.00
Price